Wren Laboratories is revolutionizing cancer diagnostics with advanced machine learning and liquid biopsy mRNA-based technology. Our goal is to provide precise, non-invasive diagnostics tailored to each patient's unique molecular profile, transforming early detection and surveillance of cancer for better patient outcomes. With over 100 patents and validation from more than 60 clinical studies, Wren has developed highly sensitive liquid biopsy mRNA gene expression-based assays. These innovative assays aid in cancer diagnosis, detect minimal residual disease (MRD), and predict tumor prognosis and therapeutic response. Our tests, including the NETest for neuroendocrine tumors and PROSTest for prostate cancer, leverage mRNA technology and AI/ML genomic assays for unparalleled molecular insights. This allows accurate detection of cancer markers, empowering personalized care. Our mRNA-based diagnostics are crucial in monitoring patients post-surgery or treatment. Wren also offers Biopharma services with AI/ML liquid biopsy genomic assays for research and companion diagnostics (CDx) development. Our RNA stabilizer tubes preserve whole blood at ambient temperature for up to 10 days, reducing clinical trial logistics. From our CLIA-certified, CAP-accredited, and NYS-licensed lab, our tests ensure high accuracy and reliability. For more information, visit our website and follow us for updates in non-invasive cancer diagnostics.